We recently compiled a list of the 15 Small-Cap Stocks Poised to Outperform in 2025. In this article, we are going to take a ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...

NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...

The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future ...

NEW YORK, NY / ACCESSWIRE / January 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...

Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...

Sangamo is on course to run out of money within months and has now lost access to up to $220 million in milestone payments ...

Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a biotechnology company specializing in genomic medicine and gene therapies, stands at a critical juncture as it navigates a complex landscape of clinical ...

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an ...